R&D
Research & Development
Kolon Pharmaceuticals is dedicated to innovating and creating value through relentless research and development.
| Country of Application | Patent Name | Application Date | Application Number |
|---|---|---|---|
| South Korea | Itraconazole composition of the powders and granulestype, its pharmaceutical preparation and method | Jun. 7, 2001 | 1020010031605 |
| Sustained-release pellet for tamsulosin hydrochloride and their method of preparation | Jan. 14, 2004 | 1020040002656 | |
| Antithrombotic Composition Comprising Cilostazol and Aspirin, and Its Preparation Method | Feb. 22, 2007 | 1020070017739 | |
| Pharmaceutical Composition and Preparation for Treatment of Metabolic Bone Disease Comprising Risedronate and Vitamin D |
Mar. 23, 2007 | 1020070028800 | |
| Food composition for enhancing exercise performance to acute and endurance exercise | Apr. 29, 2013 | 1020130047351 | |
| Orally disintegrating tablet containing mirtazapine | Dec. 31, 2013 | 1020130168527 | |
| Orally Disintegrating Tablet comprising sugar or sugar alcohol granules reformed with ethyl cellulose | May 16, 2018 | 1020180055753 | |
| Taste-masking Cinacalcet Orally Disintegrating Tablet and producing method thereof | Jul. 17, 2018 | 1020180082821 | |
| Japan | ミルタザピンを含有する口腔崩解錠 | Dec. 26, 2014 | 2014266370 |
| 口腔崩壊錠の製造方法 | Apr. 22, 2019 | 2019080927 |
| Pharmaceutical Company | Drug | Content |
|---|---|---|
| NOVARTIS | STI571(Gleevec) | World’s First targeted Therapy/BCR-ABL Inhibitors |
| NOVARTIS | PKI166 | Pre-Clinical Research on EGFR and HER2 Targeted Therapy |
| AstraZeneca | Irresa | Pre-Clinical Research on EGFR and HER2 Targeted Therapy |
| NOVARTIS | AEE788 | Development of EGFR/VEGFR Dual Inhibitors |
| ACTELION | Bosentan & Macitentan | Repositioning of cardiovascular drug to brain cancer and metastatic brain tumor treatment drug |
| GC Biopharma | Greenstatin | Advisory for GC Biopharma’s Development of New Cardiovascular Inhibitor |
| GC Biopharma | MSLN-CAR-T | Joint research on MSLN-CAR-T Cellular Treatment Drug with GC Biopharma |
| Genentech | Avastin | Pre-Clinical Research of VEGF Targeted Therapy |
| NOVARTIS | DPP-4 Inhibitor | Global Phase 3 & Phase 4 Clinical Trial Tests for Diabetes Drugs |
| KOLON TISSUEGENE | INVOSSA | Korea Local BLA Approval and US Clinical Phase 1 and 2 Clinical Trials for Osteoarthritis Treatment Drug |
| Yungjin Pharm | NAD+ Modulator | Korea Local Clinical Trial for Mitochondria Anomaly Disease Treatment Drug and License Out to NeuroVive |
| Yungjin Pharm | Yutoma | Korea Local Clinical Trials and Approval for Atopic Dermatitis Treatment Drug |
| Yungjin Pharm | YPL001 | Conducted Phase 1 and 2 Clinical Trials for Chronic Obstructive Lung Disease Natural Drugs |
| GE Healthcare | Sonazoid | Clinical Trials and US FDA NDA Approval for Liver Cancer Ultrasonic Diagnosis Drugs |
| GE Healthcare | Vizamyl | Clinical Trials and US FDA Approval for Alzheimer’s PET Diagnostic Drug (Flutemetamol) |
| Others | Involved in Development of Multiple Anti-Cancer Drugs such as CXCR7 (3 molecules) Targeted Therapy and Managed Entire Clinical Translational Trials | |
